Related Experiment Videos
Active sensitisation modifies beta-adrenoceptor reactivity in guinea-pig trachea
L Daffonchio1, A Hernandez, G Brunelli
1Institute of Pharmacological Sciences, University of Milan, Italy.
Pulmonary Pharmacology
|January 1, 1989
Summary
Beta-adrenoceptor desensitisation occurs in experimental asthma models. This desensitisation, induced by beta 2-agonists, is more pronounced in actively sensitised guinea-pig asthma models, suggesting a role in asthma development.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Immunology
Background:
- Beta-adrenoceptor desensitisation is observed in experimental models but its occurrence in clinical settings after long-term beta 2-agonist therapy remains unclear.
- Experimental models typically use normal animals, necessitating investigation in disease-specific models.
Purpose of the Study:
- To investigate beta-adrenoceptor desensitisation in an actively sensitised guinea-pig model of experimental asthma.
- To compare beta-adrenoceptor reactivity in normal versus ovalbumin-sensitised guinea-pig tracheae.
Main Methods:
- Experimental asthma model induced by active ovalbumin sensitisation in guinea pigs.
- In vitro beta-adrenoceptor desensitisation induced by isoproterenol or salbutamol administration.
- Assessment of isoproterenol and epinephrine concentration-response curves in isolated tracheae.
Main Results:
- Beta-adrenoceptor desensitisation shifted isoproterenol concentration-response curves to the right in both normal and sensitised tissues.
- Ovalbumin-sensitised tissues showed greater impairment of beta 2-mediated relaxation after desensitisation compared to normal tissues.
- The observed changes in reactivity were dependent on active sensitisation, not passive sensitisation.
Conclusions:
- Beta-adrenoceptor reactivity is modified in this experimental asthma model.
- The enhanced desensitisation in actively sensitised tissues suggests a role for this phenomenon in the pathogenesis of asthma.
- These findings may have implications for the long-term use of beta 2-agonists in asthma patients.